total compounding pharmaceuticals semaglutide / Cyanocobalamin Injection Compound Semaglutide

Ozempic Ozempic was first approved for type 2 diabetes, but many noticed meaningful weight loss, too

It has a long history of clinical use and is commonly discussed in weight-management care

It closed an oversubscribed 19.5 million series A round in November 2024 to accelerate growth and international expansion LIMBO (UK) Limbo is a weight loss program that offers a data-driven, individualised approach to weight loss

2018;20(suppl 1):5-21

Nutrionist Consultation We know that lifestyle choices are vital to weight loss success

Instead, doses increase gradually over a minimum of 20 weeks to reach the maximum, and this escalation period explains why results are modest early on